DMRA

Damora Therapeutics, Inc.

NASDAQ: DMRA · HEALTHCARE · BIOTECHNOLOGY

$29.21

+3.11% today

Updated 2026-07-30

Market cap

$1.74B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.57

Dividend yield

—

52W range

$2 – $38

Volume

0.6M

Market cap

$1.74B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.57

Dividend yield

—

52W range

$2 – $38

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.0

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

3.0

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$44.11

+51.01%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-20.60M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-61.62M	$-38.35M	$-21.44M	$-209.84M	$-27.78M
EPS	—	—	—	—	$-2.57
Free cash flow	$-43.13M	$-36.91M	$-18.62M	$-6.73M	$-20.60M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DMRA	$1.74B	26	4.3	3.0	5.0	8.0	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Damora Therapeutics, Inc. trades at $29.21. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.99, it sits in the grey zone.

Frequently asked questions

What is Damora Therapeutics, Inc.'s stock price?

Damora Therapeutics, Inc. (DMRA) trades at $29.21.

Is Damora Therapeutics, Inc. overvalued?

Damora Therapeutics, Inc. carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Damora Therapeutics, Inc. (DMRA)?

The 12-month analyst consensus target is $44.11, about 51.0% above the current $29.21. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Damora Therapeutics, Inc.'s Altman Z-Score is 2.99, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-89.50%

Beta1.47

50D MA$25.77

200D MA$23.60

Shares out0.06B

Float0.04B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DMRA vs LLY →DMRA vs JNJ →DMRA vs ABBV →Stock screener →